HHC is developing first-in-class nucleic acid-based therapies (NATs) for anything from head and neck cancer to Parkinson's disease. Our platform technology enables highly localized in vivo drug uptake with Wireless Electroporation. By using focused electromagnetic waves to manipulate the membrane of cells at a target site in the patient’s body, HHC enables a precise and highly localized drug uptake, while avoiding systemic side effects.